Immune modulation by Fas ligand reverse signaling: Lymphocyte proliferation is attenuated by the intracellular Fas ligand domain

Blood

Volumn 117, Issue 2, 2011, Pages 519-529

  Lückerath, Katharina ^a   Kirkin, Vladimir ^a   Melzer, Inga Maria ^a   Thalheimer, Frederic B ^a   Siele, Dagmar ^a   Milani, Wiebke ^a   Adler, Thure ^b   Aguilar Pimentel, Antonio ^c   Horsch, Marion ^b   Michel, Geert ^b   Beckers, Johannes ^b,c   Busch, Dirk H ^d   Ollert, Markus ^c   Gailus Durner, Valerie ^b   Fuchs, Helmut ^b   De Angelis, Martin Hrabě ^b,c   Staal, Frank J T ^e   Rajalingam, Krishnaraj ^f   Hueber, Anne Odile ^g   Strobl, Lothar J ^b   Zimber Strobl, Ursula ^b   Zörnig, Martin ^a   more..

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^g UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE C GAMMA; PROTEIN KINASE C; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR LYMPHOID ENHANCER BINDING FACTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; GENE DELETION; GENETIC TRANSCRIPTION; IMMUNE RESPONSE; IMMUNOMODULATION; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION;

EID: 78751472228     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-292722     Document Type: Article

References (51)

1. Voss M, Lettau M, Paulsen M, Janssen O. Post-translational regulation of Fas ligand function. Cell Commun Signal. 2008;6:11.
2. Fas SC, Fritzsching B, Suri-Payer E, Krammer PH. Death receptor signaling and its function in the immune system. Curr Dir Autoimmun. 2006;9:1-17.
3. Ferguson TA, Griffith TS. A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev. 2006;213:228-238.
4. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today. 1995;16(1):39-43.
5. Kavurma MM, Khachigian LM. Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ. 2003;10(1):36-44. (Pubitemid 36511831)
6. Peter ME, Budd RC, Desbarats J, et al. The CD95 receptor: apoptosis revisited. Cell. 2007;129(3):447-450.
7. Sancho-Martinez I, Martin-Villalba A. Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle. 2009;8(6):838-842.
8. Suzuki I, Fink PJ. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J Exp Med. 1998;187(1):123-128. (Pubitemid 28044827)
9. Desbarats J, Duke RC, Newell MK. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat Med. 1998;4(12):1377-1382. (Pubitemid 28553459)
10. Sun M, Lee S, Karray S, Levi-Strauss M, Ames KT, Fink PJ. Cutting edge: two distinct motifs within the Fas ligand tail regulate Fas ligand-mediated costimulation. J Immunol. 2007;179(9):5639-5643.
11. Paulsen M, Mathew B, Qian J, Lettau M, Kabelitz D, Janssen O. FasL cross-linking inhibits activation of human peripheral T cells. Int Immunol. 2009;21(5):587-598.
12. Kirkin V, Cahuzac N, Guardiola-Serrano F, et al. The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells. Cell Death Differ. 2007;14(9):1678-1687.
13. Baum W, Kirkin V, Fernandez SB, et al. Binding of the intracellular Fas ligand (FasL) domain to the adaptor protein PSTPIP results in a cytoplasmic localization of FasL. J Biol Chem. 2005;280(48):40012-40024.
14. Cahuzac N, Baum W, Kirkin V, et al. Fas ligand is localized to membrane rafts, where it displays increased cell death-inducing activity. Blood. 2006;107(6):2384-2391.
15. Fuchs H, Gailus-Durner V, Adler T, et al. The German Mouse Clinic: a platform for systemic phenotype analysis of mouse models. Curr Pharm Biotechnol. 2009;10(2):236-243.
16. Gailus-Durner V, Fuchs H, Adler T, et al. Systemic first-line phenotyping. Methods Mol Biol. 2009;530:463-509.
17. Rastelli J, Homig-Holzel C, Seagal J, et al. LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing classswitch recombination to IgG1. Blood. 2008;111(3):1448-1455.
18. Swanson CL, Wilson TJ, Strauch P, Colonna M, Pelanda R, Torres RM. Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J Exp Med. 2010;207(7):1485-1500.
19. Toellner KM, Luther SA, Sze DM, et al. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med. 1998;187(8):1193-1204.
20. Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci. 2008;65(22):3525-3544.
21. Hikida M, Kurosaki T. Regulation of phospholipase C-gamma2 networks in B lymphocytes. Adv Immunol. 2005;88:73-96. (Pubitemid 41437912)
22. Staal FJ, Luis TC, Tiemessen MM. WNT signalling in the immune system: WNT is spreading its wings. Nature Rev Immunol. 2008;8(8):581-593.
23. Jin ZX, Kishi H, Wei XC, Matsuda T, Saito S, Muraguchi A. Lymphoid enhancer-binding factor-1 binds and activates the recombination-activating gene-2 promoter together with c-Myb and Pax-5 in immature B cells. J Immunol. 2002;169(7):3783-3792.
24. Reya T, O'Riordan M, Okamura R, et al. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity. 2000;13(1):15-24.
25. Peng SL, Gerth AJ, Ranger AM, Glimcher LH. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity. 2001;14(1):13-20.
26. Ahn KS, Sethi G, Aggarwal BB. Nuclear factor-kappa B: from clone to clinic. Curr Mol Med. 2007;7(7):619-637.
27. Mittrucker HW, Matsuyama T, Grossman A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997;275(5299):540-543.
28. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398(6726):422-426. (Pubitemid 29180374)
29. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003;362(9379):205-209. (Pubitemid 36859937)
30. Durmowicz MC, Cui CY, Schlessinger D. The EDA gene is a target of, but does not regulate Wnt signaling. Gene. 2002;285(1-2):203-211. (Pubitemid 34246336)
31. Kratochwil K, Galceran J, Tontsch S, Roth W, Grosschedl R. FGF4, a direct target of LEF1 and Wnt signaling, can rescue the arrest of tooth organogenesis in Lef1(-/-) mice. Genes Dev. 2002;16(24):3173-3185.
32. Hebenstreit D, Giaisi M, Treiber MK, et al. LEF-1 negatively controls interleukin-4 expression through a proximal promoter regulatory element. J Biol Chem. 2008;283(33):22490-22497.
33. Sun M, Fink PJ. A new class of reverse signaling costimulators belongs to the TNF family. J Immunol. 2007;179(7):4307-4312.
34. Wilczynski JR, Radwan M, Kalinka J. The characterization and role of regulatory T cells in immune reactions. Front Biosci. 2008;13:2266-2274. (Pubitemid 351589251)
35. Oehme I, Neumann F, Bosser S, Zornig M. Transgenic overexpression of the Caspase-8 inhibitor FLIP(short) leads to impaired T cell proliferation and an increased memory T cell pool after staphylococcal enterotoxin B injection. Eur J Immunol. 2005;35(4):1240-1249.
36. Hahne M, Renno T, Schroeter M, et al. Activated B cells express functional Fas ligand. Eur J Immunol. 1996;26(3):721-724. (Pubitemid 26091406)
37. Lundy SK, Lerman SP, Boros DL. Soluble egg antigen-stimulated T helper lymphocyte apoptosis and evidence for cell death mediated by FasL(+) T and B cells during murine Schistosoma mansoni infection. Infect Immun. 2001;69(1):271-280.
38. Nagafuchi H, Wakisaka S, Takeba Y, Takeno M, Sakane T, Suzuki N. Aberrant expression of Fas ligand on anti-DNA autoantibody secreting B lymphocytes in patients with systemic lupus erythematosus: "immune privilege"-like state of the autoreactive B cells. Clin Exp Rheumatol. 2002;20(5):625-631.
39. Lundy SK. Killer B lymphocytes: the evidence and the potential [published online ahead of print March 5, 2009]. Inflamm Res. doi: 10.1007/s00011-009- 0014-x.
40. Arce L, Yokoyama NN, Waterman ML. Diversity of LEF/TCF action in development and disease. Oncogene. 2006;25(57):7492-7504. (Pubitemid 44885748)
41. Arimura Y, Vang T, Tautz L, Williams S, Mustelin T. TCR-induced downregulation of protein tyrosine phosphatase PEST augments secondary T cell responses. Mol Immunol. 2008;45(11):3074-3084.
42. Davidson D, Veillette A. PTP-PEST, a scaffold protein tyrosine phosphatase, negatively regulates lymphocyte activation by targeting a unique set of substrates. EMBO J. 2001;20(13):3414-3426.
43. Yang H, Reinherz EL. CD2BP1 modulates CD2-dependent T cell activation via linkage to protein tyrosine phosphatase (PTP)-PEST. J Immunol. 2006;176(10):5898-5907.
44. Blott EJ, Bossi G, Clark R, Zvelebil M, Griffiths GM. Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail. J Cell Sci. 2001;114(Pt 13):2405-2416.
45. Zuccato E, Blott EJ, Holt O, et al. Sorting of Fas ligand to secretory lysosomes is regulated by mono-ubiquitylation and phosphorylation. J Cell Sci. 2007;120(Pt 1):191-199. (Pubitemid 46206661)
46. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 1995;14(6):1129-1135.
47. He JS, Ostergaard HL. CTLs contain and use intracellular stores of FasL distinct from cytolytic granules. J Immunol. 2007;179(4):2339-2348.
48. Kassahn D, Nachbur U, Conus S, et al. Distinct requirements for activation-induced cell surface expression of preformed Fas/CD95 ligand and cytolytic granule markers in T cells. Cell Death Differ. 2009;16(1):115-124.
49. Xiao S, Deshmukh US, Jodo S, et al. Novel negative regulator of expression in Fas ligand (CD178) cytoplasmic tail: evidence for translational regulation and against Fas ligand retention in secretory lysosomes. J Immunol. 2004;173(8):5095-5102.
50. Thornhill PB, Cohn JB, Stanford WL, Desbarats J. The adaptor protein Grb2 regulates cell surface Fas ligand in Schwann cells. Biochem Biophys Res Commun. 2008;376(2):341-346.
51. Thornhill PB, Cohn JB, Drury G, Stanford WL, Bernstein A, Desbarats J. A proteomic screen reveals novel Fas ligand interacting proteins within nervous system Schwann cells. FEBS Lett. 2007;581(23):4455-4462.